BioSpace News Archive

ClorDiSys attended the 2024 MD&M West Conference in Anaheim, California to present their chlorine dioxide gas sterilization services and equipment.

Expert Systems, a leader in AI-enabled drug discovery, proudly announces a significant achievement in collaboration with Eilean Therapeutics LLC: the commencement of first-in-human trials for eiletoclax, a highly potent BCL2 inhibitor, within just three years.

ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report fourth quarter and full year 2023 financial results on February 28, 2024, after the U.S. financial markets close.

Spectral Medical Inc. is pleased to announce an extension to its supply and distribution agreement with Baxter Healthcare Corporation, a subsidiary of Baxter International Inc., originally entered into in February 2020.

Modular Medical, Inc. announced the closing of its previously announced underwritten public offering of 9,090,910 shares of its common stock, led by Manchester Explorer, L.P., which is managed by Jeb Besser, Modular Medical’s Chief Executive Officer, and Morgan Frank, a member of the Company’s board of directors, and other existing institutional investors.

Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on April 26, 2024 to holders of record on March 28, 2024.

Nevro Corp. announced that it has entered into a Cooperation Agreement with Engaged Capital, LLC, pursuant to which Kirt P. Karros has been appointed to Nevro’s Board of Directors as well as the Audit Committee of the Board effective February 20, 2024.

Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced that the Company plans to release its third quarter fiscal year 2024 financial results on Wednesday, March 6, 2024 after the close of trading.

Prothena Corporation plc, a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced the appointment of Daniel G. Welch to its Board of Directors as an independent director and Chair Designate following a comprehensive search process in connection with the board’s regular succession planning.